Literature DB >> 29909388

Lymphedema secondary to limited cutaneous systemic sclerosis.

Sónia Moreira1, Jorge Crespo1, Lèlita Santos1.   

Abstract

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterised by vascular abnormalities, immune system activation and fibrosis. Lymphatic involvement in SSc was described more recently and starts in early stages. This report describes a 46-year-old patient who developed over the last 2 years asymmetric lymphedema in lower extremities. Compromise in lymphatic drainage was confirmed by lymphoscintigraphy. She also presented Raynaud's phenomenon, a scleroderma pattern in nailfold capillaroscopy, cutaneous thickening and anticentromere antibodies, which together resulted in a new diagnosis of limited cutaneous SSc. Treatment with methotrexate, prednisolone and lymphatic drainage resulted in lymphedema improvement. To our knowledge, this is the first case of grade 2 lymphedema in the setting of anticentromere-positive limited cutaneous SSc. We highlight the importance of considering rheumatic diseases in the differential diagnosis of lymphedema. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  connective tissue disease; dermatology

Mesh:

Substances:

Year:  2018        PMID: 29909388      PMCID: PMC6011433          DOI: 10.1136/bcr-2017-224148

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Lymphatic microangiopathy of the skin in systemic sclerosis.

Authors:  A J Leu; S B Gretener; S Enderlin; P Brühlmann; B A Michel; O Kowal-Bielecka; U Hoffmann; U K Franzeck
Journal:  Rheumatology (Oxford)       Date:  1999-03       Impact factor: 7.580

2.  Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis.

Authors:  Mirko Manetti; Anna Franca Milia; Serena Guiducci; Eloisa Romano; Marco Matucci-Cerinic; Lidia Ibba-Manneschi
Journal:  J Rheumatol       Date:  2010-11-15       Impact factor: 4.666

Review 3.  Lymphangiogenesis: Molecular mechanisms and future promise.

Authors:  Tuomas Tammela; Kari Alitalo
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

Review 4.  Lymphedema and wound healing.

Authors:  E C Mallon; T J Ryan
Journal:  Clin Dermatol       Date:  1994 Jan-Mar       Impact factor: 3.541

5.  Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers.

Authors:  Alfiya Akhmetshina; Jürgen Beer; Karin Zwerina; Matthias Englbrecht; Katrin Palumbo; Clara Dees; Nicole Reich; Jochen Zwerina; Gabriella Szucs; Johannes Gusinde; Tatiana Nevskaya; Oliver Distler; Dontscho Kerjaschki; Georg Schett; Jörg H W Distler
Journal:  Arthritis Rheum       Date:  2010-05

6.  Lymphatic compression by sclerotic patches of morphea: an original mechanism of lymphedema in a child.

Authors:  Mahtab Samimi; Annabel Maruani; Marie-Christine Machet; Françoise Baulieu; Laurent Machet; Gérard Lorette
Journal:  Pediatr Dermatol       Date:  2010 Jan-Feb       Impact factor: 1.588

7.  Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase.

Authors:  Susanna Maddali Bongi; Angela Del Rosso; Mauro Passalacqua; Sara Miccio; Marco Matucci Cerinic
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-08       Impact factor: 4.794

8.  Elephantiasis nostras verrucosa in a patient with systemic sclerosis.

Authors:  S Chatterjee; L J Karai
Journal:  Clin Exp Dermatol       Date:  2009-07-03       Impact factor: 3.470

Review 9.  The treatment of lymphedema.

Authors:  E Földi
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Lymphatic and blood vessels in scleroderma skin, a morphometric analysis.

Authors:  Antonella Rossi; Francesca Sozio; Piersante Sestini; Elisabetta A Renzoni; Korsa Khan; Christopher P Denton; David J Abraham; Elisabetta Weber
Journal:  Hum Pathol       Date:  2009-12-11       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.